Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359670 · ClinicalTrials.gov registry record · Early Phase 1
Tadalafil and Sildenafil for Duchenne Muscular Dystrophy
A Early Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT01359670 is a Early Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT01359670, a Early Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study, supported by Parent Project Muscular Dystrophy, will determine if tadalafil or sildenafil can improve muscle blood flow during exercise in boys with Duchenne muscular dystrophy.
Interventions
- DRUG Sildenafil
- DRUG Tadalafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01359670
The ClinicalTrials.gov registry entry for NCT01359670 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sildenafil is the first listed.
NCT01359670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01359670 about?
NCT01359670 is a clinical study titled "Tadalafil and Sildenafil for Duchenne Muscular Dystrophy". This study, supported by Parent Project Muscular Dystrophy, will determine if tadalafil or sildenafil can improve muscle blood flow during exercise in boys with Duchenne muscular dystrophy.
What is the current status of trial NCT01359670?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2011-05. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01359670?
The interventions under investigation include: Sildenafil (DRUG), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT01359670?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.